• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics Set to Join S&P MidCap 400

    5/29/24 5:48:00 PM ET
    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $JNJ alert in real time by email

    NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    June 3, 2024

    S&P MidCap 400

    Addition

    Sarepta Therapeutics

    SRPT

    Health Care

    June 3, 2024

    S&P MidCap 400

    Deletion

    Shockwave Medical

    SWAV

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sarepta-therapeutics-set-to-join-sp-midcap-400-302158643.html

    SOURCE S&P Dow Jones Indices

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $SPGI
    $SRPT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Sarepta Therapeutics Inc.
    $SRPT
    9/22/2025$50.00Market Perform → Outperform
    BMO Capital Markets
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$22.00Underweight → Equal Weight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$13.00Mkt Perform
    Bernstein
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$37.00Perform → Outperform
    Oppenheimer
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$24.00Underweight → Neutral
    Analyst
    More analyst ratings

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief People Officer Ganesan Girish exercised 181 shares at a strike of $481.67 and covered exercise/tax liability with 73 shares, increasing direct ownership by 8% to 1,383 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    10/3/25 4:02:20 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    New insider Morikis John G claimed ownership of 599 shares (SEC Form 3)

    3 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/15/25 4:36:54 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/11/25 5:52:29 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Johnson & Johnson from Equal Weight to Overweight and set a new price target of $212.00

    10/3/25 8:30:20 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seaport Research Partners initiated coverage on S&P Global with a new price target

    Seaport Research Partners initiated coverage of S&P Global with a rating of Buy and set a new price target of $540.00

    10/1/25 9:39:03 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Johnson & Johnson upgraded by Guggenheim with a new price target

    Guggenheim upgraded Johnson & Johnson from Neutral to Buy and set a new price target of $206.00

    9/23/25 8:13:07 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    8/20/24 8:00:04 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson recommends shareholders reject "mini-tender" offer by Tutanota

    Johnson & Johnson (NYSE:JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company established pursuant to the laws of the Island of Nevis to purchase up to 500,000 shares of Johnson & Johnson common stock at a price of $145.00 per share in cash. Tutanota's offer price of $145.00 per share was well below the closing price of Johnson & Johnson common stock on September 26, 2025, the last full trading day prior to the date of the offer. Moreover, the offer is conditioned on, among other things, the closing price per share of Johnson & Johnson common stock exceeding $145.00 on the last trading day before the offer expires.

    10/10/25 4:20:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Dow Jones Indices Reports U.S. Common Indicated Dividend Payments Increase of $10.6 Billion in Q3 2025 as Dividend Growth Continues to Be Slow

    Q3 2025 U.S. common dividend increases were $14.0 billion, up 43.0% from $9.8 billion in Q2 2025 and down 0.7% from $14.1 billion in Q3 2024.Q3 2025 U.S. common dividend decreases were $3.4 billion, up 46.1% from $2.3 billion in Q2 2025 and down 25.2% from $4.6 billion in Q3 2024.Q3 2025 net indicated dividend rate change increased $10.6 billion. For the 12-months ending September 2025 U.S. common dividend increases were $57.5 billion, down 23.1% from the 12-month September 2024 period's $74.7 billion; decreases were down 36.4% to $12.4 billion compared to $19.5 billion for the prior 12-month period.The net 12-month September 2025 indicated dividend increase was $45.1 billion compared to $44

    10/10/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    CHINA DRIVES STRONGEST GROWTH IN GLOBAL FACTORY PURCHASING SINCE MID-2022, WHILE NORTH AMERICAN MANUFACTURERS COOL IN SEPTEMBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX

    Chinese manufacturers sharply increased purchasing in September, propelling Asia's supply chains to their busiest level since June 2022.In contrast, tariff-related disruptions and a softer economic outlook curbed North American manufacturing activity.Europe's recovery remains sluggish, with supply chains operating at their weakest since March.CLARK, N.J., Oct. 10, 2025 /PRNewswire/ -- GEP Global Supply Chain Volatility Index — a leading indicator tracking demand conditions, shortages, transportation costs, inventories, and backlogs based on a monthly survey of 27,000 businesses — was little changed in September (-0.38 vs -0.39 in August), indicating that global supply chains are operating be

    10/10/25 8:06:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    SEC Filings

    View All

    Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    9/8/25 7:55:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.

    SCHEDULE 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    9/8/25 11:06:08 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Johnson & Johnson

    144 - JOHNSON & JOHNSON (0000200406) (Subject)

    9/4/25 2:37:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Bentley Systems Set to Join S&P MidCap 400 and Western Union to Join S&P SmallCap 600

    NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Bentley Systems Inc. (NASD: BSY) will replace Western Union Co. (NYSE:WU) in the S&P MidCap 400, and Western Union will replace Mr. Cooper Group Inc. (NASD: COOP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 6. Rocket Companies Inc. (NYSE:RKT) acquired Mr. Cooper Group in a deal that closed today, October 1. Western Union's market capitalization is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name        Action Company Name Ticker GICS Sector October 6, 2025   S&P MidCap

    10/1/25 6:03:00 PM ET
    $BSY
    $RKT
    $SPGI
    Computer Software: Prepackaged Software
    Technology
    Finance: Consumer Services
    Finance

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Carbon Data Open Protocol (CDOP) Coalition Unveils Open-Source Data Model at Climate Week NYC to Facilitate and Scale Carbon Markets

    37 organizations including Isometric, Verra, South Pole, and Kita commit to continue supporting the adoption and development of the Carbon Data Open Protocol (CDOP) Version 1.0 Open-source data schema for project location, details & approach addresses carbon market fragmentationDeveloped in alignment with, and building upon, other data standardization initiatives, including the G20-led Common Carbon Credit Data Model (CCCDM), the CAD Trust, and the UNFCCC (relating to Article 6)NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Today at Climate Week NYC a growing coalition of carbon market participants announced the release of Version 1.0 of the Carbon Data Open Protocol (CDOP) structure to help facil

    9/23/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    S&P Dow Jones Indices Reports U.S. Common Indicated Dividend Payments Increase of $10.6 Billion in Q3 2025 as Dividend Growth Continues to Be Slow

    Q3 2025 U.S. common dividend increases were $14.0 billion, up 43.0% from $9.8 billion in Q2 2025 and down 0.7% from $14.1 billion in Q3 2024.Q3 2025 U.S. common dividend decreases were $3.4 billion, up 46.1% from $2.3 billion in Q2 2025 and down 25.2% from $4.6 billion in Q3 2024.Q3 2025 net indicated dividend rate change increased $10.6 billion. For the 12-months ending September 2025 U.S. common dividend increases were $57.5 billion, down 23.1% from the 12-month September 2024 period's $74.7 billion; decreases were down 36.4% to $12.4 billion compared to $19.5 billion for the prior 12-month period.The net 12-month September 2025 indicated dividend increase was $45.1 billion compared to $44

    10/10/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Schedules Third Quarter 2025 Earnings Announcement and Conference Call for Thursday, October 30, 2025

    NEW YORK, Oct. 2, 2025 /PRNewswire/ -- S&P Global's (NYSE:SPGI) third quarter 2025 results will be issued on Thursday, October 30, 2025 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on October 30, 2025 to discuss the Company's third quarter 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck

    10/2/25 4:00:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P 500 Q2 2025 Buybacks Declines 20% Amidst Uncertainty to $235 Billion From Q1 2025's Record $293 Billion; Q3 2025 Expenditures Expected to Increase Back to Near Record Levels

    S&P 500 Q2 2025 buybacks were $234.6 billion, as the expenditure declined 20.1% from the record Q1 2025 $293.5 billion and was down 0.6% from Q2 2024's $235.9 billionThe 12-month June 2025 expenditure was $997.8 billion and was up 13.7% from the 12-month June 2024 expenditure of $877.5 billion Utilities was the only sector to increase spending, up 16.5% over Q1 2025, Health Care reduced spending by 39.3%, Information Technology by 16.3% and Communication Services by 15.0%The net buyback 1% tax reduced Q2 2025 operating earnings, which are set to post a quarterly earnings record, by 0.39% and As Reported GAAP by 0.42%, as the 12-month cost was 0.42% and 0.45%, respectivelyNEW YORK, Sept. 17,

    9/17/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

    2/13/24 5:13:59 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care